First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.-MedSci.cn

First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.

Ishihara, M; Tono, Y; Miyahara, Y; Harada, N; Kageyama, S; Sasaki, T; Hori, Y; Soga, N; Uchida, K; Shiraishi, T; Sato, E; Kanda, H; Mizuno, T; Webster, G; Ikeda, H; Katayama, N; Sugimura, Y; Shiku, H

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务